おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Nalagenetics
company
About
Nalagenetics is a biotechnology company that provides genetic testing services.
- 11 - 50
Details
- Last Funding Type
- Non-Equity Assistant
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Nalagenetics is a health-tech company that provides genetic testing. In 2016, the company collaborated with the Indonesian health ministry to distribute 1,000 genetic test kits in five villages in Papua and West Papua. The company's tests revealed that 20% of leprosy patients in the area carry the gene responsible for potentially fatal reactions to Dapsone, an anti-leprosy medication; this discovery assisted doctors in determining which patients could be safely treated with the antibiotic.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$12.60M
Nalagenetics has raised a total of
$12.60M
in funding over 2 rounds. Their latest funding was raised on
Aug 1, 2022 from a Non-Equity Assistant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 1, 2022 | Non-Equity Assistant | — | 1 |
Google for Startups
|
— | Detail |
| Mar 25, 2022 | Series A | $12.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Nalagenetics is funded by 2 investors.
Google for Startups
and Diagnos Laboratories
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Google for Startups
|
Yes | Non-Equity Assistant |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
